GW823093C For The Treatment Of Type 2 Diabetes Mellitus

Phase 2TerminatedNCT00370942

GlaxoSmithKline159 enrolled

Overview

This study was designed to find dose response and as extension in treatment of GW823093C.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

159

Conditions

Diabetes Mellitus, Type 2

Interventions

GW823093C ADRUG

A=45 mg

GW823093C BDRUG

B=30 mg

GW823093C CDRUG

C=25 mg

Eligibility

Sex: ALLMin age: 20 YearsMax age: 74 Years

Medical Language ↔ Plain English

Inclusion criteria: * Type 2 diabetes mellitus. * Managed by diet therapy or receiving treatment with oral anti-diabetic monotherapy (excluding TZD (Thiazolidinediones)) Exclusion criteria: * Patients who have metabolic disease judged by investigator as a clinically significance * Serious cardiovascular disease or serious hepatic disease

Locations (5)

GSK Investigational Site

Hokkaido, Japan

GSK Investigational Site

Miyagi, Japan

GSK Investigational Site

Tokyo, Japan

GSK Investigational Site

Tokyo, Japan

GSK Investigational Site

Outcomes

Primary Outcomes

Efficacy variables Dose response (change from baseline in HbA1c) at stipulated date in each treatment group

Time frame: 12 weeks

Secondary Outcomes

Long term safety variables

Time frame: 64 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.